Be cautious, FluMist users

Healthwise
Share this Post

Be cautious, FluMist users

Healthwise
Share this Post

Q. Because the FluMist nasal

spray contains a live virus, people who use this form of flu vaccination

should be aware they will be contagious for quite some time. In fact,

hospital workers who use FluMist have been asked not to come to work for

up to three weeks.

A. Your concern is well taken.

FluMist uses a live but weakened virus. According to the Centers for Disease

Control and Prevention, the risk of virus transmission by FluMist users

to others is relatively low. Because the virus is weakened, the CDC says,

it's unlikely that such transmission would cause flu symptoms.

Though this risk might be small,

it seems prudent that FluMist users - for a period of time after

getting the spray - stay away from people less able to fend off infection.

Vulnerable persons include the elderly and those with weakened immune

systems.

This is the reason for limiting

the use of FluMist in the first place to healthy, younger people 5 to

49 years old.

The CDC recommends that this

"stay away" period last for one week.

Because many hospitalized patients

are in the vulnerable category, some hospitals are choosing to err on

the side of greater caution by extending the "stay away" period

up to three weeks for their employees who use FluMist.

FluMist is a new product, and

we should know more after the current flu season.

Q. You recently said that some

glucosamine-chondroitin supplements contain too much manganese and that

this might cause adverse neurologic effects with prolonged use. My glucosamine

supplement contains magnesium stearate listed under "other ingredients"

but does not say how much. Is that the same as manganese?

A. Manganese and magnesium

are two different minerals. Magnesium stearate is an additive used as

a lubricant in the manufacturing. It's classified as an inactive

ingredient.

Back

to Healthwise Home Page |

Stay Up-to-Date on What’s Fun and Important in Fayette

Newsletter

Latest Comments

VIEW ALL
Newsletter
Scroll to Top